Robert J Lyons

US Patent:

6969706, Nov 29, 2005

Filed:

May 12, 2004

Appl. No.:

10/844647

Inventors:

Chin-Ming Chang - Tustin CA, US
James Chang - Newport Beach CA, US
Robert T. Lyons - Laguna Hills CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A61K031/724

US Classification:

514 60, 514912, 514914, 514970, 536103

Abstract:

A composition comprising a cyclodextrin, a guanidine-based cationic compound, and sorbic acid is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and methods are also presented herein.

US Patent:

8039010, Oct 18, 2011

Filed:

Nov 3, 2006

Appl. No.:

11/556503

Inventors:

John T. Trogden - Anaheim CA, US
Robert T. Lyons - Laguna Hills CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A61K 38/00
A61K 31/71
A61K 9/00
A61K 47/00
A61K 39/95
A61P 27/00

US Classification:

424400, 4241451, 4241301, 514 2, 514 44 R, 514772

Abstract:

A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.

US Patent:

8318169, Nov 27, 2012

Filed:

Sep 12, 2011

Appl. No.:

13/230355

Inventors:

John T. Trogden - Anaheim CA, US
Robert T. Lyons - Laguna Hills CA, US

Assignee:

Allergen, Inc. - Irvine CA

International Classification:

A61K 39/395
A61K 38/02
A61K 38/16
A61P 27/02
A61P 27/06
A61P 9/10

US Classification:

4241421, 514 11, 4241301

Abstract:

A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.

US Patent:

8642067, Feb 4, 2014

Filed:

Apr 2, 2007

Appl. No.:

11/695527

Inventors:

John T. Trogden - Anaheim CA, US
Robert T. Lyons - Laguna Hills CA, US
James N. Chang - Newport Beach CA, US
Scott M. Whitcup - Laguna Hills CA, US

Assignee:

Allergen, Inc. - Irvine CA

International Classification:

A61F 2/00

US Classification:

424428

Abstract:

Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25 C. of at least about 10 cps or about 100 cps at a shear rate of 0. 1/second. In a preferred embodiment, the viscosity at 25 C. is in the range of from about 80,000 cps to about 300,000 cps.

US Patent:

20040152664, Aug 5, 2004

Filed:

Jan 23, 2004

Appl. No.:

10/764057

Inventors:

Chin-Ming Chang - Tustin CA, US
James Chang - Newport Beach CA, US
Michelle Luu - Anaheim CA, US
Robert Lyons - Laguna Hills CA, US
Orest Olejnik - Coto De Caza CA, US

Assignee:

Allergan, Inc.

International Classification:

A61K031/724
A61K031/573

US Classification:

514/058000, 514/179000

Abstract:

Disclosed herein are compositions comprising cyclodextrin derivatives and prednisolone and prodrugs thereof, and methods related thereto. The use of soluble polyanionic polymers such as hydroxypropylmethylcellulose and others in relation to these compositions is also disclosed. Delivery of these prednisolone-related compounds to the back of the eye via topical ophthalmic administration is also disclosed.

US Patent:

20080033351, Feb 7, 2008

Filed:

Oct 25, 2006

Appl. No.:

11/552630

Inventors:

John T. Trogden - Anaheim CA, US
Robert T. Lyons - Laguna Hills CA, US
James N. Chang - Newport Beach CA, US
Michael R. Robinson - Irvine CA, US
Werhner C. Orilla - Anaheim CA, US

Assignee:

ALLERGAN, INC. - Irvine CA

International Classification:

A61M 31/00

US Classification:

604 57

Abstract:

Ocular implant delivery assemblies are provided which include a cannula having a lumen extending therethrough, a proximal end, a proximal end opening, a distal end, a distal end opening, and a lumen extending through the cannula. A cap is provided having a closed distal end, being in contact with the outer wall of the cannula, and covering the distal end and the distal end opening of the cannula, the cap being structured to allow the distal end and the distal end opening of the cannula to pass through the cap as the cannula is passed into an eye. An ocular implant is located in the lumen. The implant may be sealed in the cannula without the addition of a liquid carrier or it may be contained in a liquid carrier medium in the cannula. The implant may be made up of a number of microparticles having different compositions or different forms. The assembly also includes a sleeve located on the proximal end of the cannula and suitable for coupling the assembly to a syringe containing a pushing gel.

US Patent:

20080097335, Apr 24, 2008

Filed:

Oct 25, 2006

Appl. No.:

11/552835

Inventors:

John T. Trogden - Anaheim CA, US
Robert T. Lyons - Laguna Hills CA, US
James N. Chang - Newport Beach CA, US
Michael R. Robinson - Irvine CA, US

Assignee:

ALLERGAN, INC. - Irvine CA

International Classification:

A61M 5/178

US Classification:

604192, 604 59

Abstract:

Ocular implant delivery assemblies are provided which include a cannula having a lumen extending therethrough, a proximal end, a proximal end opening, a distal end, a distal end opening, and a lumen extending through the cannula. A removable distal closure element is provided for closing the distal end opening, and a removable proximal closure element is provided for closing the proximal end opening. An ocular implant is located in the lumen. The implant may be sealed in the cannula without the addition of a liquid carrier or it may be contained in a liquid carrier medium in the cannula. The implant may be made up of a number of microparticles having different compositions or different forms. The assembly also includes a sleeve located on the proximal end of the cannula and suitable for coupling the assembly to a syringe containing a pushing gel.

US Patent:

20090149435, Jun 11, 2009

Filed:

Dec 7, 2007

Appl. No.:

11/952927

Inventors:

Zhengjun Wang - Irvine CA, US
Thomas M. McGrath - Claremont CA, US
Toan N. Ha - Irvine CA, US
Sam W. Lam - Oceanside CA, US
Bruce A. Firestone - Irvine CA, US
Robert T. Lyons - Laguna Hills CA, US
James N. Chang - Newport Beach CA, US
John T. Trogden - Anaheim CA, US

International Classification:

A61K 31/573

US Classification:

514180

Abstract:

Process for making a sterile, injectable pharmaceutical composition by combining triamcinolone, a buffer and a high viscosity hyaluronate.